Top

Published in:

01-04-2020 | Macular Degeneration | Original Paper

Investigation of genetic base in the treatment of age-related macular degeneration

Authors: Kalliopi Gourgouli, Ioanna Gourgouli, Georgios Tsaousis, Sofia Spai, Maria Niskopoulou, Spiros Efthimiopoulos, Klea Lamnissou

Published in: International Ophthalmology | Issue 4/2020

Abstract

Purpose

To determine whether gene polymorphisms which are associated with age-related macular degeneration (AMD) influence treatments’ response and specifically the antioxidant supplementation in dry AMD patients, as well as the anti-vascular endothelial growth factor (anti-VEGF) therapy in neovascular AMD patients.

Methods

A total of 170 patients with dry AMD and 52 neovascular AMD patients were genotyped for the following single nucleotide polymorphisms (SNPs): rs1061170/Y402H in CFH gene, rs10490924/A69S in ARMS2 gene, rs9332739/E318D and rs547154/IVS10 in C2 gene, and rs4151667/L9H and rs2072633/IVS17 in CFB gene. Treatment response was evaluated by comparing visual acuity and optical coherence tomography between baseline and at the end of the treatment.

Results

Τhe CFH/Y402H variant was associated with the response to antioxidants in dry AMD patients. Carriers of one or two CFH risk alleles displayed a lower chance of responding compared to those with no risk allele. No association of antioxidants’ response and ARMS2/A69S genotype was identified. The analysis of the C2 and CFB genetic variants (protective SNPs) revealed that antioxidant supplementation was much more effective in protective SNP carriers. In neovascular AMD patients, the analysis indicated that Y402H homozygous patients were less likely to respond to anti-VEGF therapy compared to heterozygous. Regarding the ARMS2/A69S genotype, carriers of the risk variant experienced significantly worse treatment outcome compared to wild-type patients.

Conclusion

In AMD patients, the efficacy of the antioxidant supplementation and the anti-VEGF therapy appears to differ by genotype. The detection of genetic variants, associated with treatment responsiveness, could lead to improved visual outcomes through genotype-directed therapy.

Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, Parodi MB, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR, Vision Loss Expert Group of the Global Burden of Disease S (2014) Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br J Ophthalmol 98(5):629–638. https://doi.org/10.1136/bjophthalmol-2013-304033 CrossRefPubMed

Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358(24):2606–2617. https://doi.org/10.1056/NEJMra0801537 CrossRefPubMed

Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27(4):372–390. https://doi.org/10.1016/j.preteyeres.2008.05.002 CrossRefPubMed

Age-Related Eye Disease Study Research G (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119(10):1417–1436CrossRef

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, Group AS (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57–65. https://doi.org/10.1016/j.ophtha.2008.10.018 CrossRefPubMed

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431. https://doi.org/10.1056/NEJMoa054481 CrossRefPubMed

Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379(9827):1728–1738. https://doi.org/10.1016/S0140-6736(12)60282-7 CrossRefPubMed

Al-Zamil WM, Yassin SA (2017) Recent developments in age-related macular degeneration: a review. Clin Interv Aging 12:1313–1330. https://doi.org/10.2147/CIA.S143508 CrossRefPubMedPubMedCentral

Seddon JM, Ajani UA, Mitchell BD (1997) Familial aggregation of age-related maculopathy. Am J Ophthalmol 123(2):199–206CrossRef

10.

Seddon JM, Cote J, Page WF, Aggen SH, Neale MC (2005) The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 123(3):321–327. https://doi.org/10.1001/archopht.123.3.321 CrossRefPubMed

11.

Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE, Spector TD (2002) Genetic influence on early age-related maculopathy: a twin study. Ophthalmology 109(4):730–736CrossRef

12.

Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML (2007) Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 297(16):1793–1800. https://doi.org/10.1001/jama.297.16.1793 CrossRefPubMed

13.

Shuler RK Jr, Hauser MA, Caldwell J, Gallins P, Schmidt S, Scott WK, Agarwal A, Haines JL, Pericak-Vance MA, Postel EA (2007) Neovascular age-related macular degeneration and its association with LOC387715 and complement factor H polymorphism. Arch Ophthalmol 125(1):63–67. https://doi.org/10.1001/archopht.125.1.63 CrossRefPubMed

14.

Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308(5720):421–424. https://doi.org/10.1126/science.1110189 CrossRefPubMed

15.

Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308(5720):385–389. https://doi.org/10.1126/science.1109557 CrossRefPubMedPubMedCentral

16.

Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308(5720):419–421. https://doi.org/10.1126/science.1110359 CrossRefPubMed

17.

Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH (2005) Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 14(21):3227–3236. https://doi.org/10.1093/hmg/ddi353 CrossRefPubMed

18.

Kanda A, Chen W, Othman M, Branham KE, Brooks M, Khanna R, He S, Lyons R, Abecasis GR, Swaroop A (2007) A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA 104(41):16227–16232. https://doi.org/10.1073/pnas.0703933104 CrossRefPubMed

19.

Andreoli MT, Morrison MA, Kim BJ, Chen L, Adams SM, Miller JW, DeAngelis MM, Kim IK (2009) Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration. Am J Ophthalmol 148(6):869–874. https://doi.org/10.1016/j.ajo.2009.07.002 CrossRefPubMedPubMedCentral

20.

Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A (2007) Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114(12):2168–2173. https://doi.org/10.1016/j.ophtha.2007.09.008 CrossRefPubMed

21.

Awh CC, Lane AM, Hawken S, Zanke B, Kim IK (2013) CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 120(11):2317–2323. https://doi.org/10.1016/j.ophtha.2013.07.039 CrossRefPubMed

22.

Bardak H, Bardak Y, Ercalik Y, Turkseven Kumral E, Imamoglu S, Gunay M, Ozbas H, Bagci O (2016) Effect of ARMS2 gene polymorphism on intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Genet Mol Res. https://doi.org/10.4238/gmr15049164 CrossRefPubMed

23.

Seddon JM, Silver RE, Rosner B (2016) Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis. Br J Ophthalmol 100(12):1731–1737. https://doi.org/10.1136/bjophthalmol-2016-308624 CrossRefPubMedPubMedCentral

24.

Chaudhary V, Brent M, Lam WC, Devenyi R, Teichman J, Mak M, Barbosa J, Kaur H, Carter R, Farrokhyar F (2016) Genetic risk evaluation in wet age-related macular degeneration treatment response. Ophthalmol J Int 236(2):88–94. https://doi.org/10.1159/000446819 CrossRef

25.

Spencer KL, Hauser MA, Olson LM, Schmidt S, Scott WK, Gallins P, Agarwal A, Postel EA, Pericak-Vance MA, Haines JL (2007) Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet 16(16):1986–1992. https://doi.org/10.1093/hmg/ddm146 CrossRefPubMed

26.

Maller J, George S, Purcell S, Fagerness J, Altshuler D, Daly MJ, Seddon JM (2006) Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 38(9):1055–1059. https://doi.org/10.1038/ng1873 CrossRefPubMed

27.

Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR, Smith RT, Group AMDGCS, Hageman GS, Dean M, Allikmets R (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38(4):458–462. https://doi.org/10.1038/ng1750 CrossRefPubMedPubMedCentral

28.

Francis PJ, Hamon SC, Ott J, Weleber RG, Klein ML (2009) Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J Med Genet 46(5):300–307. https://doi.org/10.1136/jmg.2008.062737 CrossRefPubMed

29.

Campbell I (2007) Chi squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med 26(19):3661–3675. https://doi.org/10.1002/sim.2832 CrossRefPubMed

30.

Age-Related Eye Disease Study 2 Research G (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309(19):2005–2015. https://doi.org/10.1001/jama.2013.4997 CrossRef

31.

Gorin MB (2012) Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics. Mol Aspects Med 33(4):467–486. https://doi.org/10.1016/j.mam.2012.04.004 CrossRefPubMedPubMedCentral

32.

Garcia M, Alvarez L, Nogacka AM, Gonzalez-Iglesias H, Escribano J, Fernandez-Vega B, Fernandez-Vega A, Fernandez-Vega L, Coca-Prados M (2015) CFH polymorphisms in a Northern Spanish population with neovascular and dry forms of age-related macular degeneration. Acta Ophthalmol 93(8):e658–e666. https://doi.org/10.1111/aos.12790 CrossRefPubMed

33.

Leveziel N, Puche N, Richard F, Somner JE, Zerbib J, Bastuji-Garin S, Cohen SY, Korobelnik JF, Sahel J, Soubrane G, Benlian P, Souied EH (2010) Genotypic influences on severity of exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 51(5):2620–2625. https://doi.org/10.1167/iovs.09-4423 CrossRefPubMed

34.

Klein ML, Francis PJ, Rosner B, Reynolds R, Hamon SC, Schultz DW, Ott J, Seddon JM (2008) CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 115(6):1019–1025. https://doi.org/10.1016/j.ophtha.2008.01.036 CrossRefPubMed

35.

Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr (2009) Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 93(5):610–613. https://doi.org/10.1136/bjo.2008.150995 CrossRefPubMed

36.

Dedania VS, Grob S, Zhang K, Bakri SJ (2015) Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration. Retina 35(3):381–391. https://doi.org/10.1097/IAE.0000000000000466 CrossRefPubMed

37.

Awh CC, Hawken S, Zanke BW (2015) Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology 122(1):162–169. https://doi.org/10.1016/j.ophtha.2014.07.049 CrossRefPubMed

38.

Chew EY, Klein ML, Clemons TE, Agron E, Ratnapriya R, Edwards AO, Fritsche LG, Swaroop A, Abecasis GR, Age-Related Eye Disease Study Research G (2014) No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology 121(11):2173–2180. https://doi.org/10.1016/j.ophtha.2014.05.008 CrossRefPubMedPubMedCentral

39.

Assel MJ, Li F, Wang Y, Allen AS, Baggerly KA, Vickers AJ (2018) Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration: independent statistical evaluations of data from the Age-Related Eye Disease Study. Ophthalmology 125(3):391–397. https://doi.org/10.1016/j.ophtha.2017.09.008 CrossRefPubMed

40.

Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, Michels S, Fleischhauer J, Berger W, Sutter F, Menghini M (2011) Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 52(7):4694–4702. https://doi.org/10.1167/iovs.10-6080 CrossRefPubMed

41.

Orlin A, Hadley D, Chang W, Ho AC, Brown G, Kaiser RS, Regillo CD, Godshalk AN, Lier A, Kaderli B, Stambolian D (2012) Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 32(1):4–9. https://doi.org/10.1097/IAE.0b013e31822a2c7c CrossRefPubMed

42.

Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E (2010) Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 16:2598–2604PubMedPubMedCentral

43.

Kitchens JW, Kassem N, Wood W, Stone TW, Isernhagen R, Wood E, Hancock BA, Radovich M, Waymire J, Li L, Schneider BP (2013) A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clin Ophthalmol 7:1987–1993. https://doi.org/10.2147/OPTH.S39635 CrossRefPubMedPubMedCentral

44.

Kaur I, Katta S, Reddy RK, Narayanan R, Mathai A, Majji AB, Chakrabarti S (2010) The involvement of complement factor B and complement component C2 in an Indian cohort with age-related macular degeneration. Invest Ophthalmol Vis Sci 51(1):59–63. https://doi.org/10.1167/iovs.09-4135 CrossRefPubMed

Title: Investigation of genetic base in the treatment of age-related macular degeneration
Authors: Kalliopi Gourgouli
Ioanna Gourgouli
Georgios Tsaousis
Sofia Spai
Maria Niskopoulou
Spiros Efthimiopoulos
Klea Lamnissou
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Macular Degeneration
Ranibizumab
Published in: International Ophthalmology / Issue 4/2020
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-019-01274-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Investigation of genetic base in the treatment of age-related macular degeneration

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

Corneal biomechanics in different age groups

NGF and CNTF expression and regulation mechanism by miRNA in acute paralytic strabismus

Hydrogen sulfide serves as a biomarker in the anterior segment of patients with diabetic retinopathy

Structural en face optical coherence tomography imaging for identification of leaky microaneurysms in diabetic macular edema

Clinical characteristics of patients hospitalized for ocular chemical injuries in Shanghai from 2012 to 2017

Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy